Andrew Hendifar, MD
6
0
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
1 terminated/withdrawn out of 6 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Role: lead
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Role: lead
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Role: lead
Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
Role: lead
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Role: lead
Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients
Role: lead
All 6 trials loaded